KIEKIDSProject reference: 282559
Funded under :
Development of an innovative paediatric formulation of an antiepileptic agent for the treatment of absence epilepsy in children
Total cost:EUR 2 776 525,6
EU contribution:EUR 2 157 071
Topic(s):HEALTH-2011.4.2-1 - Investigator-driven clinical trials on off-patent medicines for children
Call for proposal:FP7-HEALTH-2011-single-stageSee other projects for this call
Funding scheme:CP-FP - Small or medium-scale focused research project
The KIEKIDS project is dedicated to the development of an innovative paediatric formulation of an antiepileptic agent for a safe alternative treatment of absence epilepsy in children.
Development of such an age-appropriate formulation is regarded by The European Medicines Agency (EMA) to be amongst one of highest priorities for the treatment of absence seizures, using a drug with identified and documented efficacy in the target population.
The KIEKIDS project has gathered a very strong consortium of well trained and qualified partners from industry, academy, and hospital with extensive experience in drug development in clinical, pharmacological, data analysis and regulatory areas. The proposed strategy for KIEKIDS implies to develop a dedicated paediatric formulation with sustained delivery and to conduct a clinical programme, which will be endorsed by approval of the Paediatric Investigation Plan (PIP).
The consortium is coordinated by the Unit 663 of INSERM (INSERM U663), a French public organisation of research devoted to the paediatric epilepsies and brain plasticity. This consortium rallies all the competencies required to manage a paediatric drug development from the designing of an adapted formulation up to market. With its solid track record of clinical success in pharmaceutical and biotech companies, and its huge expertise in absence epilepsy, this consortium will be able to avoid the pitfalls of pharmaceutical drug development and is in a strong position to guarantee the success of the programme.
The ultimate goal of KIEKIDS is to submit in 2015 this novel age-adapted paediatric formulation as a Paediatric-Use Marketing Authorisation, a PUMA, the tool identified by the EMA to bridge the gap for off-patent drugs.
EU contribution: EUR 451 705
RUE DE TOLBIAC 101
Tel.: +33 1 40784901
Fax: +33 1 40784998
EU contribution: EUR 1 127 100
RUE GEORGES BESSE 155
30000 NIMES CEDEX 01
Tel.: +33 466 21 23 35
Fax: +33 466 21 23 35
EU contribution: EUR 279 946
RUE DU BUGNON 21
Tel.: +41 21 314 42 61
Fax: +41 21 314 42 66
EU contribution: EUR 298 320
RUE BON AIR 30
Tel.: +32 474 901 894
Fax: +32 474 901 894